Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ESG401 in advanced or metastatic solid tumors
CTR20212074Phase 2Completed
- Sponsor
- Affinity Biopharma
- Start
- Sep 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ESG401 in Nonhematologic neoplasms, sponsored by Affinity Biopharma. Started Sep 2021; status: completed.
02
Drugs
ESG401
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20212074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212074.